Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Psoriasis
•
Dermatology
How frequently or soon have you noticed TNF-a induced psoriasiform dermatitis develop? What are effective treatments for patients who do not want to change their regimen?
Related Questions
Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?
How do you approach managing nausea and GI side effects when initiating methotrexate?
How does the location or type of psoriasis affect your initial biologic choice?
What are the best biologics for a pediatric patient with extensive guttate psoriasis that is poorly controlled on topicals?
How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments?
Do you discontinue IL-17A, IL-17A/F, or IL-23 blockade in pregnant patients with psoriasis?
How do you approach treatment change in patients with psoriasis who have been stable on an IL-17 or IL-23 agent but then begin to have breakthrough skin disease?
Do you caution against starting biologics for psoriasis if patient has hepatitis A antibodies?
How do you manage a psoriatic patient previously on cimizia and now stelara with new onset atopic dermatitis (with desire for pregnancy and fertility treatments)?
How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
